HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions

Human Immunology Biosciences believes its early investment in an immunology asset is beginning to pay off, reporting positive phase 2 data of a kidney disease treatment less than six months after the company was unveiled.